# ABL Diagnostics strengthens its patent portfolio and viral safety expertise with TEXCELL

*A new strategic dimension in virology and bacteriology to enhance the safety of biological products and samples*

WOIPPY, FRANCE, September 10, 2026 /EINPresswire.com/ -- ABL Diagnostics (Euronext Paris - ISIN: FR001400AHX6), a specialist in molecular diagnostics and infectious diseases, announces the strengthening of its technology and intellectual property portfolio following the acquisition of TEXCELL's activities and assets.

This transaction brings ABL Diagnostics new strategic expertise in viral safety, complementing its longstanding molecular diagnostics activities. The Group is thus expanding its offering with new products, technologies and services in virology and bacteriology, particularly aimed at ensuring the safety and characterization of samples, sample preparations and biological products.

From pathogen detection to viral safety:
Among the acquired assets is a patented technology arising from patent application EP 10306347.5, dedicated to the quantification of infectious viruses using reference infectious standards. The technology enables the quantitative assessment of viral infectivity through host-cell response and offers potential for automation and high-throughput processing.

This technology adds a further dimension to ABL Diagnostics' capabilities in the detection, identification and molecular characterization of infectious agents: the ability to assess and manage viral risk.

“By combining the expertise of ABL Diagnostics and TEXCELL, we can now address a much broader value chain, ranging from ensuring the safety of samples and biological products to the molecular detection and characterization of pathogens. This complementarity opens up numerous opportunities with laboratories, biotechnology companies and the pharmaceutical industry.”
Mohammed Errafyqy, Sales Manager, TEXCELL

Strengthened positioning in a strategic global market:
Viral safety is a major challenge for the pharmaceutical and biotechnology industries, particularly in the development and production of vaccines, biological medicines, viral vectors, and cell and

gene therapies. The expansion of these markets, combined with increasingly stringent quality and biosafety requirements, is driving growing demand for solutions to characterize, quantify, eliminate and inactivate infectious agents.

With TEXCELL, ABL Diagnostics is therefore complementing its longstanding positioning in molecular diagnostics and infectious diseases with additional expertise in viral safety, virology and bacteriology, creating new opportunities for products, services and technological developments for laboratories and the biopharmaceutical industry.

“This acquisition significantly expands ABL Diagnostics' technological scope. Our expertise in molecular diagnostics for infectious diseases is now complemented by strong capabilities in viral safety. We therefore have a particularly complementary set of expertise enabling us not only to detect and characterize infectious agents, but also to help ensure the safety of biological products.”
Dr. Chalom Sayada, Chief Executive Officer of ABL Diagnostics

About ABL Diagnostics (ABLD)

ABL Diagnostics (ABLD) is an international company specializing in innovative molecular biology testing and comprehensive solutions for its customers:
- Molecular detection using polymerase chain reaction (PCR) - UltraGene, and
- Genotyping by DNA sequencing - DeepChek®.

ABL Diagnostics markets its full product portfolio worldwide through its own sales team and a network of exclusive distributors active across all continents. ABL Diagnostics' customers include academic clinical pathology laboratories, private reference laboratories and researchers seeking to implement an expanding range of innovative and robust microbiology solutions.

Following the acquisition of TEXCELL's activities, ABL Diagnostics is expanding its life sciences activities by integrating expertise and services dedicated to virology, biosafety testing and biopharmaceutical development.
ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategic agreement.

An expanding microbiology product portfolio:
- HIV - Drug resistance testing, including a whole-genome kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B and C - Advanced detection solutions.
- Microbiome and taxonomy - 16S/18S RNA-based analyses.
- Other viral and bacterial targets - Comprehensive molecular testing solutions.

Integrated solutions
- Real-time syndromic PCR testing
- Nadis® - Electronic patient medical record used in more than 200 hospitals in France for the

management of HIV and hepatitis.

Headquartered in Woippy, ABL Diagnostics is a French public limited company listed on Compartment B of the Euronext Paris regulated market (Euronext: ABLD - ISIN: FR001400AHX6). Its molecular biology products generate recurring revenues and cover one of the broadest portfolios of applications in microbiology.

Contacts
ABL Diagnostics SA
French public limited company with share capital of EUR 1,611,465.60
Registered office: 72C route de Thionville - 57140 WOIPPY
552 064 933 R.C.S. METZ  Tel: +33 (0)7 83 64 68 50
Email: info@abldiagnostics.com
https://www.abldiagnostics.com/

Dr Sayada
ABL Diagnostics SA
+33 7 83 64 68 50
email us here

---

This press release can be viewed online at: https://www.einpresswire.com/article/940832380

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.